Ultragenyx Pharmaceutical Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $421.0M | $174.0M | $214.0M | $132.9M | $307.6M | $713.5M | $433.6M | $113.4M |
| Accounts Receivable | $158.0M | $122.0M | $73.4M | $40.4M | $28.4M | $23.1M | $32.8M | $12.7M |
| Inventory | $52.0M | $45.0M | $34.0M | $26.8M | $16.2M | $13.0M | $11.5M | $7.1M |
| Total Current Assets | $951.0M | $817.0M | $732.2M | $883.9M | $856.6M | $1.30B | $851.0M | $522.4M |
| Property, Plant & Equipment | $244.0M | $266.0M | $290.6M | $259.7M | $141.2M | $73.5M | $44.3M | $20.0M |
| Goodwill | $44.0M | $44.0M | $44.4M | $44.4M | $44.4M | $44.4M | $44.4M | $44.4M |
| Intangible Assets (Excl. Goodwill) | $176.0M | $178.0M | $166.3M | $160.1M | $130.8M | $131.1M | $129.0M | $129.2M |
| Total Assets | $1.53B | $1.50B | $1.49B | $1.55B | $1.52B | $1.76B | $1.14B | $719.6M |
| Liabilities | ||||||||
| Accounts Payable | $31.0M | $39.0M | $42.1M | $43.3M | $17.1M | $12.9M | $12.9M | $12.3M |
| Total Current Liabilities | $384.0M | $344.0M | $280.4M | $261.2M | $181.4M | $189.6M | $103.3M | $74.7M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $1.61B | $1.24B | $1.22B | $1.19B | $599.8M | $605.2M | $481.7M | $110.7M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-4.53B | $-3.96B | $-3.39B | $-2.78B | $-2.07B | $-1.62B | $-1.43B | $-1.03B |
| Total Stockholders' Equity | $-80.0M | $255.0M | $275.0M | $352.0M | $922.6M | $1.15B | $653.8M | $608.9M |